An FDA safety review on sodium-glucose cotransporter-2 (SGLT-2) inhibitors resulted in additional warnings to the label on ketoacidosis, urosepsis, and pyelonephritis. SGLT-2 are sodium-dependent glucose transport proteins, which can be found in the kidneys.